Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

July 20, 2021

New York Stock Exchange US Consumer Staples Tobacco earnings 75 min

Earnings Call Speaker Segments

Nick Rolli

executive
#1

Good day, and thanks for being with us. We put out a press release earlier today that lays out full details about how we performed in the second quarter of 2021. That release can be found at www.pmi.com. Toward the close of today's webcast slides — which are likewise available on our site — you'll find a glossary of terms, covering the definition of reduced-risk products, or RRPs, along with adjustments, other calculations and reconciliations to the most directly comparable U.S. GAAP measures, plus extra heated tobacco unit market share data. Except where noted otherwise, whenever we mention IQOS, we mean our IQOS heat-not-burn products. Whenever we mention smoke-free products, we mean our RRPs. Growth rates given on an organic basis show underlying results without currency effects. Adjusted net revenues leave out the impact of the Saudi Arabia customs assessments covered in today's press release. One thing to keep in mind: because of U.K. takeover code requirements, on this call we don't plan to share anything further about our offer to acquire Vectura Group plc beyond what was already disclosed in the Rule 2.7 Announcement dated July 9, 2021. The Rule 2.7 Offer Announcement can be obtained at www.pmi.com. Remarks today include forward-looking statements and projections of future results. I'd point you to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. Also be aware of the additional forward-looking and cautionary statements concerning COVID-19. It's now my pleasure to introduce Emmanuel Babeau, our Chief Financial Officer. Emmanuel.

Emmanuel Babeau

executive
#2

Thanks, Nick, and hello everyone. I trust all of you on this call are doing fine and staying healthy. In the second quarter of 2021, our company achieved an exceptionally robust set of results, landing just above what we had anticipated and matching the record quarterly adjusted diluted EPS from Q1, which was $1.57, even as the global pandemic kept posing difficulties. What stood out most was how powerfully IQOS kept expanding — it accounted for 13% of shipment volumes and close to 30% of adjusted net revenues, up from 24% during the equivalent quarter a year earlier. HTU shipment volumes rose 30% versus the same period last year and 12% sequentially over the preceding quarter, hitting 24.4 billion units, with robust gains throughout important markets. We likewise kept switching adult smokers over at a solid rate, exceeding an approximate 20 million users, and nearly 15 million of them have adopted IQOS and quit smoking. On an organic basis, combustible net revenues increased 4% during Q2, which mirrored a partial volume recovery against a soft quarter last year along with dependable pricing, though market mix partly counteracted that. Our adjusted operating income margin widened considerably across both Q2 and the entire first half. Although we anticipate commercial investment will rise in the latter half of the year, this keeps us solidly positioned for robust organic results in 2021, and an anticipated currency tailwind should deliver extra growth when measured in dollars. Notably, this forecast also enabled us to reaffirm last month our share buyback program, targeting between $5 billion and $7 billion across 3 years. We're also thrilled to share that IQOS ILUMA, the upcoming generation of IQOS, is set to debut in Japan next month. As we discussed during Investor Day in February, this marks a significant advance in category innovation as we work to speed up our progress toward a smoke-free future; when it comes to long-term growth, we additionally made a key move to strengthen our modern oral and Beyond Nicotine operations in recent weeks via the proposed purchase of Fertin Pharma and Vectura, which I'll address again shortly. Now for the headline figures. Our Q2 adjusted net revenue climbed 11.6% organically, or roughly 18% when expressed in dollars. That mirrors both the rebound of the combustible segment across numerous markets relative to the severely disrupted second quarter of 2020, including the requirement for elevated inventory levels, and the ongoing momentum of IQOS, with 35% organic growth in RRP net revenue. On the combustible side, pandemic effects remained severe in certain areas and sales routes — notably South and Southeast Asia, South America, and worldwide Duty Free. Even so, as much of the globe reopened, social occasions came back to some degree, and our market share improved from one period to the next. Net revenue per unit grew organically at a solid 5.1%, driven by IQOS accounting for a larger portion of what we sell, plus pricing across both combustible products and RRPs. Our adjusted operating income margin was up 270 basis points on an organic basis. That reflects IQOS getting bigger and more profitable, along with better combustible volume, helpful pricing, savings from productivity efforts including lower device costs, and reduced commercial spending tied to the pandemic. Our adjusted diluted EPS came in at $1.57, representing organic growth of 17.8% and a dollar-based increase of 21.7%, which is a really strong result. Turning to the first half overall, adjusted net revenue rose almost 12% in dollar terms and 7.1% on an organic basis. We pulled that off even though the first quarter made for a harder comparison, and it lines up with the second-quarter drivers I already covered, plus consistent expansion of IQOS, whose momentum throughout the pandemic has been remarkable — most notably the fact that the number of users in the EU Region has doubled since the close of 2019. We delivered robust organic growth of just about 6% in net revenue per unit, which again speaks to our evolving business mix and our pricing. Our H1 adjusted operating income margin, on an organic basis, climbed 440 basis points. Even though we plan to step up commercial investments during the back half of the year, as we said back at Q1, that is still a terrific result. For the first half, adjusted diluted earnings per share rose 19.6% on an organic basis and 25.6% in dollar terms, which is also a very strong outcome; that leads me into our 2021 guidance. With total industry volume for combustible products improving following the relaxation of pandemic-related restrictions, we now anticipate a stronger organic result for the year than we had before. On net revenue, our organic growth projection is being raised to a range of plus 6% to plus 7%, which sits at the top of the earlier range. Our guidance for organic adjusted OI margin growth stays at approximately two hundred basis points higher. For organic adjusted diluted EPS, we're lifting the growth forecast to a range of twelve to fourteen percent, which translates to fifteen to seventeen percent when measured in dollars. We're still anticipating HTU shipment volume in the ninety-five billion to one hundred billion unit range. Because momentum in our market is strong, we need to keep inventory duration steady, and we're getting ready for the IQOS ILUMA launch that involves a different consumable, we anticipate full-year HTU shipments will come in a bit above IMS volumes. The organic EPS growth we're projecting—which accounts for an estimated currency tailwind of about $0.18 based on current rates—brings our adjusted diluted EPS outlook up to a range of $5.97 to $6.07. No significant effects from buybacks or acquisitions are factored into this guidance. Our Board recently gave the green light to kick off a three-year repurchase initiative, targeting between $5 billion and $7 billion, set to begin after we report Q2 earnings. Keep in mind, the proposed deals for Fertin Pharma and Vectura have no bearing on this program. Now let's walk through a few of the main H2 assumptions that support this guidance. We're expecting that most of our major markets will have mostly moved past COVID-related restrictions, which should help drive stronger industry volumes. In places where pandemic-related difficulties are still substantial—Indonesia and the Philippines stand out, along with specific markets in South America—our assumption is that things won't worsen materially beyond where they stand right now. Our expectation also remains that Duty Free will see no real bounce-back during this year, since intercontinental and Asian travel are still weak. When travel picks up inside customer regions like the European Union, the impact is only marginal. On top of that, after combustible pricing came in at roughly plus 3% during the first half, we see a slightly gentler trajectory across the second half. For the entire year, our forecast still stands at a variance of plus 2% to plus 3%. That mirrors ongoing pandemic-related difficulties in specific markets, particularly South and Southeast Asia. The second half additionally confronts a demanding pricing comparison stemming from the 2020 VAT reduction in Germany as well as new excise tax terms in Australia. Device supply keeps being constrained by the worldwide semiconductor shortage. Although the total effect stays manageable, we've modified our device assortment so that consumer availability suffers less. Our guidance already incorporates this dynamic, and we keep watching the situation carefully. Even with all of this, our business has numerous growth drivers, and we feel confident about our capacity to keep delivering solid top line progress.

Emmanuel Babeau

executive
#3

This outlook for revenue incorporates an anticipated increase in device shipments as well as the introduction of IQOS ILUMA, and that combination means gross margin will expand by less than what we saw in the first half. As I said earlier, we're also going to ramp up commercial spending in several priority areas — portfolio expansion and launches of products like IQOS ILUMA and IQOS VEEV, building understanding and awareness of the smoke-free category, and quite a few commercial development initiatives. Versus the first half, we expect roughly $300 million to $400 million in additional outlays, and that's going to weigh on our H2 OI margin, though for the full year we still look for a very strong expansion of about plus 200 basis points. Looking at Q3 on its own, our EPS guidance is $1.50 to $1.55. Finally, our expectation for 2021 operating cash flow stays at approximately $11 billion, using prevailing exchange rates and depending on year-end working capital needs. Before I go deeper into our results, I'd like to call out a few favorable regulatory moves from the quarter. The idea that smoke-free products can reduce harm keeps gathering momentum. Recent examples include the Philippines House of Representative passing a broad differentiated regulatory framework for RRP, and Pakistan putting in place differentiated excise treatment for heated tobacco product. Over in Mexico, the prohibition on importing and exporting electronic nicotine delivery system no longer covers heated tobacco devices, so we can restart bringing in IQOS devices. Although we're pleased that the German government has acknowledged the key principle of differentiating combustible cigarette from smoke-free product based on potential health impact, in our view the announced excise tax changes on heated tobacco are misguided, since they give consumers less reason to move from cigarette to less harmful alternatives. We're also aware of differing positions among the major political groups there as the full election approaches, and we hope a new government might revisit that decision. More broadly across the EU, we stay optimistic that revising the tobacco excise directive will bring about greater harmonization in how noncombustible product is treated structurally, factoring in the relevant good practices and experience that member states have accumulated. Let me return now to the quarterly results. Q2 total shipment volume rose by plus 6.1%, and for H1 it was up plus 1.1%. That mirrors ongoing strong growth in HTUs of plus 30%, reaching 24.4 billion unit in Q2, powered by the EU Region, Japan, Russia, Ukraine and encouraging momentum in recently launched market in the Middle East. For the second quarter, HTU shipments ran about 1.4 billion units above IMS volume, which reflects the need to keep inventory duration in the growing business, sea freight lead times and the initial shipment of ILUMA consumable. Our Q2 cigarette volume grew plus 3.2%, which mirrors recovery across a number of key market relative to a notably weak prior year quarter, when pandemic-related disruption was at its peak. Even though our cigarette share went up from one period to the next, we still run into certain pressures on market share tied to specific factors, plus the impact of market mix, and I'll address that shortly. Thanks to how well IQOS has performed, heated tobacco units made up 13.3% of all the volume we shipped in H1, versus 11% during 2020, 8% during 2019, and 5% during 2018; we anticipate that this share will keep rising as momentum for IQOS stays favorable, which gives us a strong engine for growing both revenue and margin. The mix of what we sell is shifting quickly, which keeps us on the path toward our goal of turning into a company that is majority smoke-free by 2025. Smoke-free products represented close to 30% of our adjusted net revenue during the quarter and in H1, up from 23% in H1 2020. IQOS devices represented roughly 5% of the $4.4 billion in RRP net revenues, which mirrors longer replacement cycles and fewer purchases of a second device among existing users, driven by better battery life, functionality, and reliability, along with lower device prices in certain markets as we get ready for IQOS ILUMA. The organic growth of plus 7.1% in H1 net revenue, on shipment volume growth of plus 1.1%, shows the twin engines propelling our top line. The first is pricing on combustible products, and in certain markets on HTU, net of the lower device pricing I just referenced. The second is the growing mix of HTUs in our business, which carry higher net revenue per unit and keep delivering substantial growth. And as we explained at Investor Day, this becomes an increasingly powerful driver as our transformation speeds up. Let me now turn to the driver behind our first half margin expansion. Starting with gross margin, which grew by plus 340 basis points on an organic basis. Several levers drive this, as explained in prior quarters, among them the mix effect from HTU and pricing across our portfolio. Our considerable work on manufacturing and supply chain efficiency is paying off, more than offsetting the impact of declining combustible volume, with roughly $300 million of gross productivity savings delivered in H1. That marks a strong start on the journey toward our target of $1 billion over 2021 to 2023. Alongside that came strong SG&A efficiency, with our adjusted H1 marketing, administration and research cost 90 basis points lower as a percentage of adjusted net revenue on an organic basis; this mirrors the ongoing digitalization and simplification of our business processes, including our IQOS commercial engine and more efficient ways of working. We delivered roughly $120 million toward our 2021 to 2023 target of $1 billion in gross SG&A savings before inflation and reinvestment. Turning now to combustible. We hold the leading international portfolio by market share and by brand strength. That gives us a formidable platform to accelerate IQOS growth through our commercial infrastructure, industry expertise, and ability to communicate with adult smokers where permitted. So it matters that we maintain our leadership through selective investment while we also drive return through pricing and efficiency. Even though we saw solid performance in places such as Mexico, Saudi Arabia, and Turkey, our cigarette share for Q2 was still down versus a year ago. More than half of that decline came from market mix, which mirrors our heavy weighting toward a market like the Philippine, plus our limited footprint in some emerging markets that are bouncing back strongly, such as Bangladesh. What matters is that our share rose sequentially from the first quarter, and we anticipate that upward path will carry on across the second half. This mirrors a partial bounce-back from COVID's effect on social occasions, where Marlboro is over-represented, along with border closures and travel. That said, the recovery we anticipate also gets support from portfolio initiatives, among them the value segment, and from Marlboro's lasting strength. Our ongoing aim is to stabilize our share within the cigarette category over time, with HTU gains layered on top. Now let me briefly address the South and Southeast Asia region. As we discussed three months ago, following a tough 2020, particularly in Indonesia, the volume headwinds have been easing. Even so, the pandemic is still a significant problem across the region, with lockdowns returning in a number of places. Daily consumption remains under where it stood before the pandemic, and pricing conditions continue to be difficult.

Emmanuel Babeau

executive
#4

We still anticipate an increase in volumes for Indonesia during this year as conditions in the industry get better, and we're encouraged by the recent market share gains we've seen in the Tier 1 segment, which is where we compete. In Q2, our share overall was roughly flat compared to the prior quarter in both Indonesia and the Philippine, and our portfolio plans aim at recovering more share through the rest of the year. Turning to RRPs, IQOS kept expanding at a robust pace in Metro Manila, finishing with a share above 1% for HEETS. Across the region as a whole, we're still set to achieve positive organic net revenue growth from April through December, just as we described during our Q1 call. Now shifting to how IQOS has performed. We calculate the number of IQOS users stood at 20.1 million on June 30. Following the extraordinary gain of roughly 1.5 million adult users during the first quarter, another 1 million or more joined in Q2, and over 2.5 million have been added year-to-date, extending the acceleration observed in the latter half of 2020. The faster shift we made toward digital and remote engagement throughout the pandemic, together with the powerful momentum behind the IQOS brand, is delivering results. We also estimate that among that total, 73%, equivalent to 14.7 million adult smokers, have made the switch to IQOS and quit smoking, while the rest are at differing stages of conversion. The robust conversion figures especially show how IQOS 3 DUO has become more widespread, since it provides a better user experience than earlier versions of the device. Through introducing innovations like IQOS ILUMA, we aim to reach even greater conversion rates as time goes on. This expansion in users once more demonstrates broad-based momentum throughout every major IQOS geography, among them the EU Region, Japan and Russia. It likewise shows how our offering has been enriched and the category has been segmented through new products and additional price points, on both sides of our original HTU offering; within the EU Region, HEETS share during the second quarter came to 5.5% of combined cigarette and HTU industry volume, which is 1.6 points above Q2 of last year. As we noted during the previous quarter, we anticipated that sequential HTU share would be roughly aligned with the first quarter, because seasonality and pandemic-driven swings in the combustible market would have an effect. The trends underneath stayed solid, as Q2 HTU IMS volume climbed more than 50% versus a year earlier and roughly 11% higher sequentially once adjustments are made for estimated trade inventory movements; we anticipate a comparable pattern in the third quarter, with headline share about flat against vigorous underlying growth. This outstanding result takes in robust gains throughout the region, with Italy and Poland standing out as key contributors; we keep expanding our EU Region IQOS user base, which has doubled since the beginning of 2020 in spite of the pandemic, reaching more than 6.3 million. Robust results carried on in Russia, where users grew 8% sequentially in Q2 and our HTU share climbed 1.3 points to hit 7.3%. Just as in the EU, sequential share may be skewed by the combustible market. Once adjusted for estimated trade inventory movement, this indicates IMS growth near 30% or more versus a year earlier. Following IQOS's impressive strides and wider geographic reach over the past year, Russia's heated tobacco segment has become sizable and is expanding. Such a strongly favorable trend inevitably draws rivals. And, as previously observed in places such as Japan, aggressive price-cutting by competitors may spark first-time trial among consumers; our user numbers keep climbing, and thanks to our current pricing-tier lineup plus the upcoming release of IQOS ILUMA, we foresee plenty of opportunity for continued robust expansion. Though our earnings calls have traditionally centered on Russia, HTU growth is widespread throughout Eastern Europe, with Ukraine, Kazakhstan and Southeast Europe making notable contributions. Here we present the strong regional growth pattern overall in adjusted IMS. Keep in mind that because of recent international sanctions, IQOS can no longer be sold in Belarus, where we posted a Q2 offtake share in Minsk of nearly 7%. We keep observing quarter-over-quarter volume gains for our Heat and Fiit ranges in Russia and Ukraine. Furthermore, lil SOLID and Fiit consumables keep bolstering user acquisition. In Russia and Ukraine alike, most consumers buying a lil device are smokers trying the smoke-free category for the first time, with a high rate of conversion, matching IQOS, aided by our IQOS conversion infrastructure. Given this achievement, we also rolled out lil SOLID in 5 additional Eastern European markets during this quarter, with more markets slated for later in the year. In Japan, the adjusted total tobacco share for our HTU brands rose by plus 2.3 points compared with the same quarter a year earlier and by 0.2 points quarter over quarter to reach 21%, underscoring the strength of our price-tier lineup and wide SKU range after the October 2020 price rise. IMS volume, adjusted for estimated trade inventory movement, climbed roughly plus 5% quarter over quarter once fewer selling days in the first quarter were taken into account; we still anticipate solid underlying gains in users and consumer offtake, backed by the August launch of IQOS ILUMA. As in earlier years, with another excise hike in October 2021, there could be unevenness in the timing of IMS and consumer offtake between the third and fourth quarters; during H1, the heated tobacco category overall accounted for roughly 29% of the adjusted total Japanese tobacco market, while IQOS held a high share of the segment and captured the vast majority of the category's growth. Beyond robust growth in markets where we already operate, our smoke-free products keep expanding geographically. This lets us offer access to better alternatives to a growing number of adult smokers as we pursue a presence in 100 markets by 2025. Our second-quarter launches in Kyrgyzstan and Uzbekistan, featuring both IQOS and lil products, bring the total count of markets where PMI smoke-free products can be purchased to 67, more than half of which lie outside the OECD. Innovation stands as the central force behind our ongoing success in smoke-free products. We're really looking forward to bringing IQOS ILUMA to market, which is the next generation of IQOS, and that launch happens next month in Japan. With the success that IQOS 3 DUO has had as our foundation, we're confident this device—simple and intuitive—will make switching easier and drive higher conversion among legal-age smokers, thanks to Smartcore internal induction heating technology. During Investor Day, we laid out that ILUMA would be offered in multiple device formats and would have a dedicated range of HTU consumable. IQOS 3 DUO's continued success nearly 2 years after it launched shows that meaningful innovation can deliver a durable, positive effect on growth. Additional market launches for IQOS ILUMA are planned throughout the rest of this year and into 2022. Of course, with any major new innovation—and this is what we saw with earlier version of IQOS—the unit cost profile for IQOS ILUMA devices and consumable starts out higher, though we anticipate improvement as scale grows. That pattern is factored into our guidance assumptions; we're still commercializing IQOS VEEV, making good progress in the first group of market, where we began in our own channel with a taste variant and nicotine level range that was initially limited. IQOS VEEV is a premium product that delivers a superior experience.

Emmanuel Babeau

executive
#5

As we've shared before, IQOS's commercial setup lets us roll out effectively and broadly via a tailored route-to-market strategy. As distribution and the consumable lineup begin to grow, we're noticing greater adoption and unmistakably favorable feedback from consumers compared with rival offerings. We intend to enter another market before this year ends, and we'll keep piloting age verification tech in chosen markets. Beyond heated tobacco and e-vapor, back in February we stated our plan to move into the small yet rapidly expanding nicotine pouch segment within this year. To supplement what we develop in-house, we've made 2 key acquisitions aimed at creating a foundation of science, technology and manufacturing capability and advancing our modern oral platform. The initial one was AG Snus, wrapped up in the second quarter. AG Snus holds a fairly modest branded modern oral lineup, giving us a toehold in that category. Furthermore, the planned purchase of Fertin Pharma would grant us a variety of promising oral delivery technologies and capabilities, several of which might be used in the modern oral nicotine arena. We'll share more updates on our commercial intentions here before the year is out. I'd also like to revisit our Beyond Nicotine strategy, first laid out at Investor Day. We identify substantial opportunities in neighboring spaces through our 2 targeted corridors: self-care wellness, which includes botanical; and health therapeutic, projected to represent an addressable market near $65 billion come 2025. The planned acquisitions of Fertin Pharma and Vectura could let us speed up growth of our development abilities in novel inhaled and oral product formulation, all while their respective CDMO operations keep expanding. Fertin offers a variety of promising oral delivery technologies, such as pouches, gum and lozenges, usable across both modern oral nicotine and Beyond Nicotine, particularly for self-care wellness items. Through Vectura, we'd obtain differentiated proprietary technology alongside pharmaceutical development know-how to supply a wide array of complex inhaled treatments. Vectura brings highly complementary human capital, technology, top-tier infrastructure and deep expertise in inhalable formulation and device design, development and analysis, drug device combination and pharmaceutical management processes and systems. These planned acquisitions would completely harness PMI's current strengths in life science, product innovation and clinical know-how tied to inhalation. Such deals could also boost our advancement on key sustainability goals. First, strengthening our modern oral capabilities is a crucial enabler for widening the reach and access of our smoke-free alternatives to adult smokers globally. Second, cultivating a robust Beyond Nicotine business stands as a major aim as we work to create commercially viable products delivering a net positive impact on society. Turning to ESG and sustainability at large; we firmly believe investor engagement can propel positive change. Because of PMI's distinctive sustainability and transformation narrative, we've stepped up our own outreach. Back in May, we came out with our second integrated report. It gives a full, detailed, and transparent picture of the sustainable value we generate and the progress we're making against our purpose and target — among them our single most significant pledge: to phase out cigarettes. Then on June 2, we ran a dedicated sustainability webcast. There we discussed how our transformation and our financial results line up fundamentally with tackling the impact we have on society. We presented the newest research drawing on real-world data about a possible link between an accelerated decline in cigarette volume and reductions in certain diseases in Japan. We restated our dedication to diversity, equity and inclusion as a vital enabler of success down the road. Our 2025 road map keeps moving forward, and in Q2 two developments stood out: our second certified carbon-neutral factory, located in Switzerland, which brings us one step nearer to carbon neutrality by 2025, and the release of our eco-design principle as we aim to do our part in the circular economy. To wrap up, having posted 1% total volume growth and 7% organic revenue growth in H1, we've lifted our 2021 organic growth outlook to plus 6% to plus 7% for net revenue and plus 12% to plus 14% for adjusted diluted EPS. An excellent performance is within reach. Beyond that, we keep putting money into the future. Right away, that means IQOS ILUMA arriving in Japan next month and in additional markets later this year. We're also funding the expansion of our smoke-free product range and our geographic footprint. That matters greatly as we work to speed up the count of adult smoker who move to better alternative, with a growing positive effect on society. On top of that, we're putting money into tomorrow's capabilities, as shown by our 2 recent proposed acquisition, which give us a comprehensive development platform spanning our Beyond Nicotine focus areas. Last, we remain dedicated to giving cash back to shareholder via dividend and share repurchase, consistent with our goal of delivering sustainable value and return to investor as we continue to — as we continue our journey toward becoming a majority smoke-free business. Thank you very much. I'm now more than happy to take your questions.

Chris Growe

analyst
#6

Great results this period. If you don't mind, I'd like to pose a couple of inquiries. Let me begin with this: IQOS ILUMA is set to debut shortly in Japan, and my assumption is that additional markets will follow. During this quarter, as I understand it, shipments exceeded consumption. Do you anticipate that pattern continuing? You referenced inventory building, I recall. Is that still probable during the latter half of the year? Or has enough stock already been accumulated to support that introduction?

Emmanuel Babeau

executive
#7

Thanks, Chris. No, I'd say part of what happened in this Q2 involved getting ready for the launch; looking at the remainder of the year, as things stand, we anticipate IMS and shipments being better matched; therefore we don't foresee additional significant gaps appearing in H2.

Chris Growe

analyst
#8

All right. Then I have one thing about the combustible segment, and I realize you provided solid information there. What I'm wondering is this: your overall share in combustibles came in weaker. I believe you said that eventually you anticipate that share leveling off. I'd like to understand whether you believed it was possible to level off the share you hold in combustibles during this year. And along those lines, perhaps you could offer additional context regarding how pricing is trending and how fierce competition currently is within combustibles. In my view, that could be one element behind the reduced pricing your business is getting in that space.

Emmanuel Babeau

executive
#9

Certainly, Chris. Regarding the goal of leveling off the share we hold within the CC segment, or CC category, that goal is definitely one we hold. Naturally, what we aim to achieve is a leveling off measured against the prior year. Sequentially, quarter against quarter, we are leveling off; and it's encouraging that the Q2 share figure reflects this sort of gain compared with Q1; measured against the prior year, we have not yet achieved a leveling off. That goal is one we hold. Over the quarters ahead, things will shift gradually, and we'll find out at what point we can get there. Still, that is unmistakably something we intend to keep chasing; regarding how pricing is trending. As you've observed, we got off to a solid start this year. Q2 remained fairly strong. Setting Indonesia aside, we report a price effect of roughly 5%, which is unmistakably favorable. H2 becomes tougher, as we've been signaling, when it comes to the basis for comparison. Germany saw a VAT reduction. Australia has a varying pattern when it comes to excise duty hikes; so those things will come into play. And we will additionally keep watching how things stand as, with luck, we leave the COVID crisis behind, and we'll find out precisely what the timing looks like and how that departure unfolds. Yet we recognize that numerous economies will remain considerably affected by it. So naturally we'll be watching how well our customers can keep up with price hikes, and that will surely shape what we decide about raising prices. So I'd put it this way: we're going to keep watching how things develop. We're going to observe what's taking place. There will surely be questions too about how inflation moves in various places, and we'll factor those in. So at this point a great deal remains uncertain, yet we'll factor all of it in as we watch and make our decision about raising prices. Even so, we have been signaling that following a 3% rise in H1, we do reaffirm the overall range of 2% to 3% for the whole year, meaning we anticipate, specifically and partly owing to harder comps in H2, an H2 that might prove less favorable where price increases are concerned than H1.

Michael Lavery

analyst
#10

I'd like to pose a few questions regarding Indonesia. One builds on part of the pricing conversation, I suppose. You flagged it, clearly, as something offsetting some of the positive pricing. Could you help us grasp the situation there a bit more clearly, and what lies ahead — what should we expect?

Emmanuel Babeau

executive
#11

Certainly. Keep in mind, Indonesia proved to be a really difficult market in the prior year, severely impacted by the pandemic; that doesn't mean, sadly, that the nation has emerged from the crisis; and up until lately, there have been fresh announcements of lockdowns and restrictions; it's likely that last year's impact was so severe that we're up against what is probably an easy comparison base. Yet the conditions there are definitely not back to normal. Even so, what we've observed is definitely an easing of conditions, once again, likely because of that easy comparison; we ourselves are performing well in the premium segment, which we refer to as Tier 1, where excise duty is higher, and we're picking up share there. That's what makes it possible for us to expand our volume in the current year. But at the same time, we're also, regrettably, witnessing the Tier 2 category, the one with lower taxes, that continues to make gains and is probably approaching a 30% market share. At the close of last year, it stood at roughly 25%, 26%. So that works in the opposite direction. And with luck, this will get fixed through changes to the excise duty policy implemented by the government; but naturally, we have no updates on that, and we can't say whether or when it will occur. So that's the scenario we're dealing with in Indonesia. There's unmistakably an improvement compared with last year. That doesn't mean the climate regarding the potential for raising prices is turning favorable. But at minimum, it's no longer the sort of heavily negative market it once was for us in the prior year.

Michael Lavery

analyst
#12

So, just to make sure about your pricing — are you telling us no increases are coming through at all? Or has it actually been cuts that you've made?

Emmanuel Babeau

executive
#13

Duty going up is hitting us; as a result, our prices are going up, yet the effect remains negative. That explains why the price impact we report differs depending on whether Indonesia is included or excluded. All told, the effect is still somewhat negative.

Michael Lavery

analyst
#14

Understood — so the added charges aren't completely covering the higher duty in that market?

Emmanuel Babeau

executive
#15

Right.

Michael Lavery

analyst
#16

Moving on to IQOS in Indonesia. I realize no launch has been announced by you there. The Internet can be a strange beast. Yet we've located roughly twelve shops in Jakarta that appear very legitimate and use highly official-sounding wording. Are those resellers of items sourced from elsewhere? Or is there some kind of soft opening happening there? Could you provide a picture of where IQOS stands in Indonesia at present?

Emmanuel Babeau

executive
#17

No official launch has taken place. An IQOS club exists where a few users might come together. Indonesia, as you're aware, is above all a kretek market. And although we definitely aim to create a dedicated heat-not-burn product for kretek, no release has happened so far. So when we do that, naturally we'd serve just a portion of the population — those with enough buying power to manage the existing devices — plus a modest number of non-kretek smokers, so to speak, though that represents a tiny slice of consumers. That may be the thing you're noticing. But at this point, there's no formal worldwide rollout, so to speak.

Gaurav Jain

analyst
#18

So I've got a few things to ask. First, regarding the outlook you gave at Investor Day — more than 9% EPS growth across 2021 to '23 — and it's obvious you're running well ahead of that this year, at nearly 13%. How are we supposed to read that? What I'm trying to figure out is whether a deceleration is coming over the next 2 years, since you've got those tax gap-closures in Germany that are going to hit high cost realization in that market next year, and maybe in certain other European markets too? Or do those things have nothing to do with the numbers.

Emmanuel Babeau

executive
#19

Well, thanks for asking, Gaurav. I believe you're reaching too far. At the time of the Investor Day, we shared this 3-year guidance and objective — more than 9%. We've gotten off to a strong beginning, since for the first year we're indeed aiming at 12% to 14%. That's plainly higher than 9%, so as I see it, for the moment we're in line with the overall beyond 9%. And that tells me we're definitely on a good path toward delivering the more than 9%; but I don't perceive any conflict between the more than 9% and what is surely good news, namely the strong start in 2021.

Gaurav Jain

analyst
#20

Understood. And should additional European tax closures of that kind materialize, what would the consequences be for your ability to hit the EPS growth target you've provided?

Emmanuel Babeau

executive
#21

Well, obviously anyone can construct any scenario they like. Responding to the most dramatic one is hard, but my view is that we've allowed for this, and we've consistently stated it — a narrowing, happening gradually, of the excise duty differential between combustible cigarettes and heat-not-burn products is something we've built into the guidance. Price increases are within our power. We've said repeatedly that IQOS, along with the consumable sold for it, is a premium offering, delivering a genuinely better experience to the user, which is why it carries a premium price positioning too. Right now, because excise duty is lower, quite often the consumable ends up costing less than a premium combustible brand such as Marlboro. That situation could obviously shift, and we have room to raise prices. Meanwhile, an increasing number of governments and regulators keep voicing the view that combustible and heat-not-burn ought to be treated differently, since heat-not-burn is the superior option — and that ought to serve as an incentive encouraging smokers to switch into the heat-not-burn category and adopt a better product for themselves. So our belief is that reductions will occur in certain markets, though not necessarily in every one. An expansion of the gap is another possibility we could imagine. That hasn't shown up lately within the EU, yet we have observed it taking hold elsewhere, and over the longer horizon we remain convinced a meaningful differential will persist between the two, entirely warranted by the fact that these products are superior. So that's a lengthy reply, essentially saying we stand ready to offset any likely narrowing of the gap. Some of it, we figure, is bound to occur regardless — Germany is one illustration. And equally, we expect a widening, shall I say, consensus that combustible and heat-not-burn products deserve to be clearly differentiated.

Gaurav Jain

analyst
#22

Absolutely. Let me also squeeze in a brief question about Japan. In October, we'll see the price gap-closure and the tax gap-closures, and that's going to push a lot of volume into the market, which will be shifting around. Plus, you're bringing out IQOS ILUMA. So could there be an opportunity to introduce a cheaper IQOS model — perhaps repositioning IQOS 3 DUO at a lower price — to grab that volume coming from the cigarillo segment, which will likely migrate?

Emmanuel Babeau

executive
#23

Of course, Gaurav, through IQOS ILUMA, we're going to enhance the premium tier for heat-not-burn. As we've said repeatedly, this will be a genuine, let's say, significant shift for consumers. For them, it will clearly mean a huge, huge step forward, eliminating what pain points remain. So naturally, that's where our attention is right now. We think the upside is enormous, as we've been pointing out; and down the road, depending on how things develop in the market, we'll obviously assess whether it makes sense to roll out new devices positioned differently. Our ultimate aim, as we've mentioned on multiple occasions, is definitely, in any scenario, to achieve complete coverage across the market spectrum. Ranging from the most premium positioning all the way to more affordable, design-to-cost, straightforward products that obviously provide an experience below the premium level but still offer good value and a sufficiently good experience for another kind of customer, shall we say. So Japan won't be an exception to our intent to cover, again, the entire market, spanning premium, medium, and even low-price positioning.

Bonnie Herzog

analyst
#24

I'd like to return to the topic of guidance for a moment. There are a few things I'm hoping you can clarify. When I look at this, you've lifted your full-year EPS outlook because you anticipate that industry volumes are getting better. Yet it still suggests a fairly notable slowdown in growth during the back half, even though you're up against a comparatively simpler comparison. You did point to certain factors, such as added expenses tied to the ILUMA launch and possibly some pressure on gross margin given that you expect to move more devices in the second half. So I simply want to be certain I grasp every positive and negative factor, or any extra pressures you foresee in that period. And I'd also like some clarification. Regarding buybacks, you noted that your guidance excludes a significant effect from any share repurchases. I just want to confirm whether that means you won't repurchase shares as vigorously during the latter part of this year, or whether repurchases simply aren't factored into the guidance whatsoever. I only want to be sure I've got that right.

Emmanuel Babeau

executive
#25

Of course, Bonnie. That's quite clear. Let me begin with the buyback so there's no confusion. No, no; we aren't providing any form of guidance or assumption about what the buyback will be. As we've stated, we're aiming to remain extremely flexible. And honestly, any scenario regarding the size of the buyback in H2 could be considered. Yet exactly because we wish to preserve that flexibility, we don't want to attach any sort of assumption regarding the buyback amount for H2. So that's truly how you ought to interpret it. Turning now to the H2 margin compared with H1, since I assume that's really what you're asking about. I believe you began to capture nicely the rationale behind a margin trajectory that differs. Still, I'm glad to walk through each component. What will surely be shared between H1 and H2 is robust momentum in top line alongside ongoing favorable movement, naturally, within our IQOS business. We still contend with, in the CC business as well, a somewhat easier comparison from last year. So that ought to affect how our CC business evolves; we keep enjoying the pleasant mix effect coming from IQOS expansion on our revenue per stick. So that will remain. And naturally, that's why we're increasing the guidance for revenue organic growth to 6% to 7%. I mean, it reflects our confidence in sustained robust momentum for revenue growth in H2; then there's another component that might differ. As I mentioned when responding to an earlier question about price, we foresee H2 potentially being tougher than the 3% price increase on the CC business that we achieved in H1; so that's plainly one factor. Another factor is the productivity level. You've observed the $300 million figure for H1; our goal is $1 billion across a 3-year span. Clearly, that $300 million isn't something you can count on repeating, so to speak, every 6-month stretch; some of this year's productivity was weighted toward the front. That doesn't mean we aren't aiming to deliver solid productivity in H2 as well, though not necessarily matching the $300 million seen in H1; so that becomes yet another factor. On top of that, there's everything stemming from the ILUMA launch, and on the margin I actually see 2 effects. First, whenever a new product is introduced — true across any business, any industry — your costs aren't yet optimized. You lack the volume needed to fully amortize the entire investment. Your processes haven't been fully optimized either. So increased cost tied to the ILUMA rollout will weigh on the gross margin. Naturally, this will fade with time. I can't say with precision how many months that takes. Still, roughly 18 to 24 months tends to be the standard horizon, I'd say, for reaching full productivity following an innovation. So that will affect H2; additionally, as we mentioned, we'll be selling more devices, including ILUMA devices. Revenue gets a lift from that, yet the gross margin effect won't match what a consumable delivers. And naturally, that touches the gross margin rate. One more item that's certainly top of mind for me: the $300 million to $400 million in additional investment during H2 compared with H1. These investments will naturally target areas where they can move the needle for the company. That means innovation, commercial and marketing capacity, and further digitizing our business and the company. That's where the money is headed. So all of these factors need to be weighed to grasp why the margin trajectory differs between H1 and H2. That said, we are of course still pursuing very strong growth in revenue, OI, and adjusted EPS during H2, naturally.

Bonnie Herzog

analyst
#26

Alright. That was genuinely useful, and I'm grateful for all of it. So clearly, there are plenty of pluses and minuses. Still, on the whole, with the guidance having been raised, you're feeling quite confident about the momentum and about the better industry volumes. So that's a positive sign. If I can, I'd like to pose a second question about the competitive landscape, particularly when I consider what Japan Tobacco is up to with the launch of their new Ploom X. And from what it sounds like, they intend to bring it to market at a fairly deep discount in order to encourage trial. Now this roughly lines up with ILUMA's rollout in Japan; so I simply want to grasp your approach when it comes to how ILUMA is positioned, especially regarding price. On the whole, how worried are you about intensifying competition? And how sure are you that you'll be able to hold onto share and, in the end, keep gaining share?

Emmanuel Babeau

executive
#27

Yes, Bonnie. That is, naturally, a really solid question and I'm glad to go into more detail. Above all, and this is likely the key point in what I'll say, we're genuinely pleased to witness competition really treating the heat-not-burn category as a major priority now; and showing, I believe, greater dedication and involvement behind this category. We believe that a common view on the need for us to jointly eliminate cigarettes and create improved products for smokers is a route, without a doubt, to speed up the path toward unsmoking the world; so watching competitors recognize that this is an excellent category, that it addresses smokers' needs and expectations, and that they're adding more innovation and more investment into it, that's simply wonderful. And I believe we're starting to observe, in certain geographies where rivals boosted their spending, that the market's overall expansion is speeding up; and naturally, since we capture a lion's share of that, it's very welcome news. That said, clearly, what matters to the smoker is being able to discover, through heat-not-burn technology and offerings, something that replicates as closely as possible what they get from a combustible cigarette. And that's precisely where our technology, our ability to innovate, makes a huge difference; and that's likely where a portion of the competition is having some difficulty, which explains why a few of them think they must cut prices on their product to gain any traction. So what does that produce? Well, ultimately, it produces the situation where you might get a trial because the device costs next to nothing and the consumable is less expensive. Yet if that fails to measure up, if it can't deliver the enjoyment or the upside you get from an IQOS session—and even more so with IQOS ILUMA—then people might go back to IQOS, or they might simply return to combustible cigarettes, since they feel it just isn't good enough compared with what they truly like. That's why it isn't about serving as the mechanism for turning smokers toward heat-not-burn; you end up with reduced average consumption for each device and weaker loyalty. So our conviction remains solid that ultimately the correct technology paired with the correct experience is what will move most smokers to adopt a better product and enter the heat-not-burn segment. We think this is precisely the proposition we put forward with IQOS, and that gives us assurance in our ability to hold onto a large share of the market. This doesn't rule out our offering a more basic device as well, since we keep our innovative strength, aimed—as I mentioned—at varying levels of purchasing power and varying expectations. Still, without question, we'll keep setting the pace on the premium side, where a superior experience is delivered.

Pamela Kaufman

analyst
#28

I was hoping you could go into more detail about what you plan to do with the higher investment during the back half of the year — specifically, which initiatives that money will support. What portion goes toward ILUMA as opposed to VEEV or the other reduced-risk products? And regarding how much will be spent, that $300 million to $400 million figure, does it mainly tie to the Japan launch? Should we annualize that incremental investment level for next year as you move into more markets?

Emmanuel Babeau

executive
#29

Thank you, Pamela. I should say I completely get your interest, and that you'd like more visibility into this additional $300 million to $400 million; unfortunately, I'll have to let you down, since — as you might expect — this is highly sensitive, and revealing those specifics isn't something we wish to do. Still, I'm glad to tell you that our investments are going where they will drive the top line, meaning higher volume and more smokers converting over to IQOS. Some of that sum certainly supports the IQOS ILUMA rollout, though that isn't the whole story. Commercial efforts are in there too, since we're seeing quite a few markets come back toward some degree of normalcy. I wouldn't claim we've arrived fully, yet there's clearly more justification to step up marketing and commercial work again, and that matters a great deal. Innovation is another area where we're speeding up, with additional funds going to life science and to expanding our footprint in the RRP category in particular. That forms part of the step-up. We've also indicated — though this is far more marginal — that we might need to reinvest very selectively in certain spots on CC where that's feasible. It'll be a minor slice of the added spending, I'd say, yet stabilizing our market share remains our aim. So with all that, Pamela, you truly have what sits behind the $300 million to $400 million; and no, you don't have to annualize it as a given. That said, let's be clear: we'll bring ILUMA to far more countries next year, during 2022. I can't go into detail right now about what the investment plan will look like. Even so, I'd expect that yes, we definitely intend to put money in with a strong return from this new offering and new technology. So next year's investment will feel some effect. Keep in mind, even so, that we have a highly ambitious effort aimed at generating $1 billion in efficiency on SG&A. We aim to be very dynamic on revenue. As a result, across a 3-year span, our target is to bring the SG&A and revenue ratio down substantially, creating a lever for stronger profitability. And naturally, with all this investment included, that stays a major ambition of ours.

Pamela Kaufman

analyst
#30

Thanks, that's quite useful. My next question: could you walk us through why the Americas got this new management setup? I'm wondering whether it shifts, even slightly, what the company focuses on in that region. Do we expect anything different in how IQOS gets rolled out across the U.S.? Or in the overall approach to the American market? Especially since Deepak Mishra comes from a strategy and M&A background.

Emmanuel Babeau

executive
#31

Thank you for pointing out how talented Deepak is. Everyone here is delighted that he's stepping into this new role. It really underscores the opportunity we believe exists across the Americas on a global scale. In particular, naturally, for the U.S., we intend to continue coordinating closely with Altria regarding IQOS. We've already signaled that we might hold certain ambitions, especially where IQOS VEEV is concerned. So please forgive me for not going into further detail there, but it definitely reflects our view that the U.S. is plainly a market where reduced-risk products hold substantial promise, and we aim to be part of realizing that promise.

Vivien Azer

analyst
#32

Starting off, I'd like to ask about VEEV. Could you give us more detail and share whatever early observations you have? I realize it's only just begun. For the shoppers who are trying that item, though, do they tend to be existing IQOS users? Are they people who just started using IQOS? Or are they completely fresh to the platform overall? Any additional observations would really help.

Emmanuel Babeau

executive
#33

Of course, Vivien. So, yeah, regarding VEEV, what we've done is essentially what I'd describe as a gentle introduction, and there are several reasons for that; our goal is to understand this category; we're gaining knowledge across lots of areas, among them confirming age, something we consider to be of the utmost importance. Our clear first step was to position VEEV as a good addition for certain people already using IQOS heat-not-burn, particularly in situations involving poly usage. That felt like a logical step for individuals already familiar with IQOS, its technology, and the excellent experience the IQOS brand delivers. I believe we're now entering a new phase; past that opening step, we're receiving excellent responses from shoppers indicating that what stands out isn't merely the sleekness of the look, but the complete experience, the standard of the item, which holds up very favorably when we run comparisons against rivals. So it's definitely time to push harder toward our goals. That will involve additional launches, naturally, plus creating more flavors; so following this initial foray into the category, you can count on us to definitely raise our ambitions when it comes to vaping.

Vivien Azer

analyst
#34

Great. My next question concerns how we're deploying capital; it has been some time since the business made this many purchases so quickly. Are you confident that you've covered the untapped areas or expertise shortfalls within your portfolio? Or is it likely that further small-scale buys will follow?

Emmanuel Babeau

executive
#35

What I'd say, Vivien, is that once we complete the planned purchase of Fertin and Vectura, we will truly establish an extremely solid foundation for our 2 goal in inhaled therapeutics and self-care wellness — a foundation that would be notably robust from a life science standpoint. On the life science side, that would be excellent. That is definitely how we see things at present regarding this matter.

Emmanuel Babeau

executive
#36

Okay, so I'll wrap up with a few main takeaways. To start, even though some markets are bouncing back from the pandemic more slowly, we're glad to share that our performance in the first half was very strong, featuring an all-time high for adjusted diluted EPS along with an increase to our 2021 guidance. Next, IQOS keeps growing impressively, and we're still set to hit our goal of 95 billion to 100 billion units this year. Then, our combustible segment is showing sequential improvement as pandemic recovery takes hold across numerous important markets. Finally, we're moving toward a significant milestone within our Beyond Nicotine strategic vision, which is part of transforming our business. Thanks once more for being with us, and we'll speak again soon.

Operator

operator
#37

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.